Medtronic (NYSE:MDT – Get Free Report) will likely be announcing its Q2 2027 results before the market opens on Tuesday, November 24th. Analysts expect the company to announce earnings of $1.33 per share and revenue of $9.48 billion for the quarter. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Parties can check the company’s upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Tuesday, November 24, 2026 at 7:30 AM ET.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. Medtronic’s revenue for the quarter was up 13.7% on a year-over-year basis. On average, analysts expect Medtronic to post $5.98 EPS for the current fiscal year and $6.35 EPS for the next fiscal year.
Medtronic Stock Up 0.1%
Shares of MDT opened at $102.92 on Tuesday. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33. The stock’s 50 day moving average is $93.89 and its two-hundred day moving average is $88.49. The firm has a market cap of $131.65 billion, a P/E ratio of 17.66, a PEG ratio of 2.36 and a beta of 0.56.
Medtronic Announces Dividend
Medtronic News Roundup
Here’s some of the latest news about MDT:
- Positive Sentiment: Medtronic plans to acquire privately held Contego Medical for $380 million. Contego develops treatments for carotid artery disease and peripheral thrombectomy; the deal would expand Medtronic’s vascular portfolio and build on an existing U.S. distribution partnership. Medtronic to buy Contego Medical for $380M
- Negative Sentiment: Wall Street Zen lowered its rating on Medtronic shares, a potentially negative sentiment signal. The article listing does not specify the revised rating or rationale. Medtronic Stock Rating Lowered by Wall Street Zen
Insider Activity
In related news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. This trade represents a 8.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 61,903 shares of company stock worth $5,889,203 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have recently issued reports on MDT. BTIG Research decreased their target price on Medtronic from $100.00 to $99.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a report on Monday. TD Cowen reissued a “buy” rating and issued a $110.00 price target on shares of Medtronic in a report on Wednesday, September 30th. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Wednesday, October 14th. Finally, Truist Financial reaffirmed a “hold” rating and set a $99.00 price objective (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $102.88.
View Our Latest Analysis on MDT
About Medtronic
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Featured Stories
- Five stocks we like better than Medtronic
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
